Related Experiment Video
Updated: Oct 5, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
COVID-19 in CKD Patients: Report from India
Nikita Pawar1, Vaibhav Tiwari1, Anurag Gupta1
1Department of Nephrology, Sir Ganga Ram Hospital, New Delhi, India.
Insights
Hospitalized patients with chronic kidney disease (CKD) face a high mortality rate from COVID-19, especially those with severe disease or requiring renal replacement therapy.
Area of Science:
- Nephrology
- Infectious Diseases
- Critical Care Medicine
Background:
- Limited data exists on coronavirus disease-2019 (COVID-19) outcomes in non-dialysis-dependent chronic kidney disease (CKD) patients.
- COVID-19 primarily presents as an acute respiratory illness, but its impact on CKD populations is not well-defined.
Purpose of the Study:
- To investigate the clinical characteristics and outcomes of hospitalized CKD patients with COVID-19.
- To identify factors associated with mortality in this vulnerable patient group.
Main Methods:
- A single-center retrospective observational study.
- Included consecutive non-dialysis CKD patients (eGFR <60 mL/min/1.73 m²) admitted with COVID-19 between April and July 2020.
Main Results:
- Out of 30 patients, 50% had CKD stage 5, and the overall mortality rate was 53.3%.
- 83.3% developed acute kidney injury on CKD, and 67% required renal replacement therapy (RRT), with poor prognosis for RRT patients.
- High LDH, IL-6, and lymphopenia were associated with fatal outcomes; severe COVID-19 cases had an 11% survival rate.
Conclusions:
- Hospitalized CKD patients exhibit a high mortality rate due to COVID-19.
- Severity of COVID-19 and need for RRT significantly impact survival in CKD patients.
Background:
COVID-19 is a novel acute infection that is mainly manifested as acute respiratory disease. Information on coronavirus disease-2019 (COVID-19) in CKD patients who are not on dialysis is very limited. We are reporting a single-center observational study on the effect of COVID-19 in CKD patients.
Methods:
A single-center retrospective study with consecutive patients who had eGFR <60 mL/min/1.73 m2 (CKD-EPI) admitted with COVID-19, from April to July 2020 were included.
Result:
A total of 30 patients were included in the study. Patients of CKD stage 5, 4 and 3 were 50%, 13.3%, and 36.6%, respectively. The mortality rate was 53.3%. Category wise, 9 were in mild; 3 in moderate, and 18 were in the severe COVID category. Twenty-five patients (83.3%) developed acute on CKD. Twenty patients (67%) required renal replacement therapy (RRT). The prognosis of patients who required RRT was poor. High LDH and IL-6 were significantly associated with mortality. Lymphopenia, present in 50% of cases was associated with fatal outcome. There was a 100% survival rate in mild to moderate cases and 11% in severe cases.
Conclusion:
Mortality among hospitalized CKD patients is high.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention

